These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
655 related articles for article (PubMed ID: 31542863)
1. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma. Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863 [TBL] [Abstract][Full Text] [Related]
2. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma? Armocida D; Pesce A; Frati A; Santoro A; Salvati M J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239 [TBL] [Abstract][Full Text] [Related]
3. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284 [TBL] [Abstract][Full Text] [Related]
4. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
5. Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts. Umehara T; Arita H; Yoshioka E; Shofuda T; Kanematsu D; Kinoshita M; Kodama Y; Mano M; Kagawa N; Fujimoto Y; Okita Y; Nonaka M; Nakajo K; Uda T; Tsuyuguchi N; Fukai J; Fujita K; Sakamoto D; Mori K; Kishima H; Kanemura Y Acta Neuropathol Commun; 2019 Jun; 7(1):99. PubMed ID: 31215469 [TBL] [Abstract][Full Text] [Related]
6. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668 [TBL] [Abstract][Full Text] [Related]
7. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation. Armocida D; Frati A; Salvati M; Santoro A; Pesce A Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of genetic alterations in distinguishing IDH-wildtype glioblastoma from lower-grade gliomas: Insight from next-generation sequencing analysis of 479 cases. Lee B; Hwang S; Bae H; Choi KH; Suh YL Brain Pathol; 2024 Sep; 34(5):e13234. PubMed ID: 38217295 [TBL] [Abstract][Full Text] [Related]
9. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma. Karsy M; Guan J; Huang LE J Neurosurg; 2019 Jan; 130(1):56-66. PubMed ID: 29547090 [TBL] [Abstract][Full Text] [Related]
10. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667 [TBL] [Abstract][Full Text] [Related]
11. Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data. Lasica AB; Jaunmuktane Z; Fersht N; Kirkman MA; Dixon L; Hoskote C; Brandner S; Samandouras G World Neurosurg; 2021 Jul; 151():e217-e233. PubMed ID: 33866029 [TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105 [TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature. Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699 [TBL] [Abstract][Full Text] [Related]
14. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas. Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770 [TBL] [Abstract][Full Text] [Related]
15. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma. Vivas-Buitrago T; Domingo RA; Tripathi S; De Biase G; Brown D; Akinduro OO; Ramos-Fresnedo A; Sabsevitz DS; Bendok BR; Sherman W; Parney IF; Jentoft ME; Middlebrooks EH; Meyer FB; Chaichana KL; Quinones-Hinojosa A J Neurosurg; 2022 Jan; 136(1):1-8. PubMed ID: 34087795 [TBL] [Abstract][Full Text] [Related]
16. Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma. Higa N; Akahane T; Hamada T; Yonezawa H; Uchida H; Makino R; Watanabe S; Takajo T; Yokoyama S; Kirishima M; Matsuo K; Fujio S; Hanaya R; Tanimoto A; Yoshimoto K Cancer Med; 2023 Jan; 12(1):49-60. PubMed ID: 35695190 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of STAT3 gene expression in patients with glioblastoma tumors: a study from Western India. Trivedi T; Panchal K; Bhalala N; Trivedi P J Egypt Natl Canc Inst; 2022 Jul; 34(1):30. PubMed ID: 35844028 [TBL] [Abstract][Full Text] [Related]
18. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526 [TBL] [Abstract][Full Text] [Related]
19. Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas. Liu EM; Shi ZF; Li KK; Malta TM; Chung NY; Chen H; Chan JY; Poon MF; Kwan JS; Chan DT; Noushmehr H; Mao Y; Ng HK Brain Pathol; 2022 Nov; 32(6):e13107. PubMed ID: 35815721 [TBL] [Abstract][Full Text] [Related]
20. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Stichel D; Ebrahimi A; Reuss D; Schrimpf D; Ono T; Shirahata M; Reifenberger G; Weller M; Hänggi D; Wick W; Herold-Mende C; Westphal M; Brandner S; Pfister SM; Capper D; Sahm F; von Deimling A Acta Neuropathol; 2018 Nov; 136(5):793-803. PubMed ID: 30187121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]